GlobeNewsWire
26 Sept 2026, 03:01 UTC · 1h ago
Verdict
Headline takes no side. We score BIDU −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Capricor Therapeutics is facing a securities class action lawsuit alleging it failed to disclose that the FDA had not agreed to changes in the statistical analysis plan for Deramiocel prior to its BLA resubmission.
Priced inpress release dated Sep 25 mentions lawsuit already filed
More negative than 95% of claims this week
The lawsuit claims there was a substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy due to these undisclosed analysis changes.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inpress release dated Sep 25 mentions lawsuit already filed
So whatAs Deramiocel is the company's lead asset, a regulatory rejection would likely lead to a severe valuation haircut and potential financing gaps.
More negative than 85% of claims this week
The deadline for investors to move the Court to serve as lead plaintiff in the securities class action is September 28, 2026.
Newpress release dated Sep 25
So whatThe narrow 3-day window until the deadline may trigger short-term volatility as institutional holders evaluate their legal standing.
More negative than 63% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is being targeted in a securities class action lawsuit notice.
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit alleging misleading statements regarding clinical data and FDA approval risks for Deramiocel.
More negative than 95% of ticker scores this week
The company is being targeted in a securities class action lawsuit notice.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
—
BIDU hasn't traded since this ran. Last close $87.33 (Sep 25); the reaction starts at the next open.
BIDU chart →
